Aduhelm In Medicaid: States Must Cover, CMS Official Says
Executive Summary
Medicaid’s pharmacy director says the Biogen Alzheimer’s drug is ‘currently a covered outpatient drug.’ As the payer of last resort, Medicaid could find itself significantly impacted by a Medicare national coverage decision.
You may also be interested in...
MACPAC ‘Undeterred’ By Lukewarm Reception Of Accelerated Drug Approval Recommendation
Executive director Schwartz suggests Congress may turn its attention to the advisory commission’s proposal to revise Medicaid coverage for drugs approved under the accelerated approval pathway in the next year or two.
Medicare Coverage Analysis Of Alzheimer’s Drugs Begins With Focus On Outcomes, Patient Eligibility
Proposed reimbursement decision to be released by 12 January 2022, with a final decision the following April. Biogen's Aduhelm expected to be covered in the interim. Medicare will not consider the cost of treatment in the analysis, but cost may have been a factor in initiating the process.
US Medicare Plans 'Can' Cover Wegovy, CMS Says, But Will They?
Medicare is making clear that Part D ‘can’ cover GLP-1 inhibitors that are approved for cardiovascular indications – but in language that seems to leave plans considerable discretion for now. The formulary review process for 2025 may be a more important milestone for changes.